Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06544785 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

106

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Zanubrutinib Oral Product
DRUG: Obinutuzumab

Sponsor

PETHEMA Foundation